These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 32915656)

  • 1. Metallo therapeutics for COVID-19. Exploiting metal-based compounds for the discovery of new antiviral drugs.
    Cirri D; Pratesi A; Marzo T; Messori L
    Expert Opin Drug Discov; 2021 Jan; 16(1):39-46. PubMed ID: 32915656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In Vitro Anti-SARS-CoV-2 Activity of Selected Metal Compounds and Potential Molecular Basis for Their Actions Based on Computational Study.
    Cirri D; Marzo T; Tolbatov I; Marrone A; Saladini F; Vicenti I; Dragoni F; Boccuto A; Messori L
    Biomolecules; 2021 Dec; 11(12):. PubMed ID: 34944502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening of Severe Acute Respiratory Syndrome Coronavirus 2 RNA-Dependent RNA Polymerase Inhibitors Using Computational Approach.
    Dhankhar P; Dalal V; Kumar V
    J Comput Biol; 2021 Dec; 28(12):1228-1247. PubMed ID: 34847746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progress and pitfalls of a year of drug repurposing screens against COVID-19.
    Sourimant J; Aggarwal M; Plemper RK
    Curr Opin Virol; 2021 Aug; 49():183-193. PubMed ID: 34218010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytopathic SARS-CoV-2 screening on VERO-E6 cells in a large-scale repurposing effort.
    Zaliani A; Vangeel L; Reinshagen J; Iaconis D; Kuzikov M; Keminer O; Wolf M; Ellinger B; Esposito F; Corona A; Tramontano E; Manelfi C; Herzog K; Jochmans D; De Jonghe S; Chiu W; Francken T; Schepers J; Collard C; Abbasi K; Claussen C; Summa V; Beccari AR; Neyts J; Gribbon P; Leyssen P
    Sci Data; 2022 Jul; 9(1):405. PubMed ID: 35831315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular Insights into Small-Molecule Drug Discovery for SARS-CoV-2.
    Su H; Zhou F; Huang Z; Ma X; Natarajan K; Zhang M; Huang Y; Su H
    Angew Chem Int Ed Engl; 2021 Apr; 60(18):9789-9802. PubMed ID: 32729180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting SARS-CoV-2 Main Protease: A Computational Drug Repurposing Study.
    Baby K; Maity S; Mehta CH; Suresh A; Nayak UY; Nayak Y
    Arch Med Res; 2021 Jan; 52(1):38-47. PubMed ID: 32962867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What is holding back the development of antiviral metallodrugs? A literature overview and implications for SARS-CoV-2 therapeutics and future viral outbreaks.
    de Paiva REF; Marçal Neto A; Santos IA; Jardim ACG; Corbi PP; Bergamini FRG
    Dalton Trans; 2020 Nov; 49(45):16004-16033. PubMed ID: 33030464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drugs, Metabolites, and Lung Accumulating Small Lysosomotropic Molecules: Multiple Targeting Impedes SARS-CoV-2 Infection and Progress to COVID-19.
    Blaess M; Kaiser L; Sommerfeld O; Csuk R; Deigner HP
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33670304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach.
    Molavi Z; Razi S; Mirmotalebisohi SA; Adibi A; Sameni M; Karami F; Niazi V; Niknam Z; Aliashrafi M; Taheri M; Ghafouri-Fard S; Jeibouei S; Mahdian S; Zali H; Ranjbar MM; Yazdani M
    Biomed Pharmacother; 2021 Jun; 138():111544. PubMed ID: 34311539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What Are the Odds of Finding a COVID-19 Drug from a Lab Repurposing Screen?
    Edwards A
    J Chem Inf Model; 2020 Dec; 60(12):5727-5729. PubMed ID: 32914973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A transferable deep learning approach to fast screen potential antiviral drugs against SARS-CoV-2.
    Wang S; Sun Q; Xu Y; Pei J; Lai L
    Brief Bioinform; 2021 Nov; 22(6):. PubMed ID: 34081143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent Development in Small Molecules for SARS-CoV-2 and the Opportunity for Fragment-Based Drug Discovery.
    Mahato S
    Med Chem; 2022; 18(8):847-858. PubMed ID: 35156586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Raltegravir, Indinavir, Tipranavir, Dolutegravir, and Etravirine against main protease and RNA-dependent RNA polymerase of SARS-CoV-2: A molecular docking and drug repurposing approach.
    Indu P; Rameshkumar MR; Arunagirinathan N; Al-Dhabi NA; Valan Arasu M; Ignacimuthu S
    J Infect Public Health; 2020 Dec; 13(12):1856-1861. PubMed ID: 33168456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drugs repurposing for SARS-CoV-2: new insight of COVID-19 druggability.
    Debnath SK; Debnath M; Srivastava R; Omri A
    Expert Rev Anti Infect Ther; 2022 Sep; 20(9):1187-1204. PubMed ID: 35615888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiviral drug discovery: preparing for the next pandemic.
    Adamson CS; Chibale K; Goss RJM; Jaspars M; Newman DJ; Dorrington RA
    Chem Soc Rev; 2021 Mar; 50(6):3647-3655. PubMed ID: 33524090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of known drugs as potential SARS-CoV-2 Mpro inhibitors using ligand- and structure-based virtual screening.
    Federico LB; Silva GM; da Silva Hage-Melim LI; Gomes SQ; Barcelos MP; Galindo Francischini IA; Tomich de Paula da Silva CH
    Future Med Chem; 2021 Aug; 13(16):1353-1366. PubMed ID: 34169729
    [No Abstract]   [Full Text] [Related]  

  • 18. Drug Discovery of Small Molecules for the Treatment of COVID-19: A Review on Clinical Studies.
    Goel B; Bhardwaj N; Tripathi N; Jain SK
    Mini Rev Med Chem; 2021; 21(12):1431-1456. PubMed ID: 33371848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of Potent SARS-CoV-2 Inhibitors from Approved Antiviral Drugs via Docking and Virtual Screening.
    Chtita S; Belhassan A; Aouidate A; Belaidi S; Bouachrine M; Lakhlifi T
    Comb Chem High Throughput Screen; 2021; 24(3):441-454. PubMed ID: 32748740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of ACE2-Spike Interaction by an ACE2 Binder Suppresses SARS-CoV-2 Entry.
    Shin YH; Jeong K; Lee J; Lee HJ; Yim J; Kim J; Kim S; Park SB
    Angew Chem Int Ed Engl; 2022 Mar; 61(11):e202115695. PubMed ID: 35043545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.